SEC Extends Compliance Date to Help Broker-Dealers Fully Test and Implement Daily Reserve Computation Requirement
- 49
Washington, D.C.--(Newsfile Corp. - June 25, 2025) - The Securities and Exchange Commission today voted to extend the compliance date to June 30, 2026, for the amendments to Rule 15c3-3 (the broker-dealer customer protection rule) that the Commission adopted on Dec. 20, 2024. The amendments require certain broker-dealers to increase the frequency of required reserve computations under Rule 15c3-3 from weekly to daily. The compliance date for these required daily reserve computations was originally Dec. 31, 2025.
“The days of unreasonable deadlines have passed,” said SEC Chairman Paul S. Atkins. “By extending this compliance date, we are giving broker-dealers additional time to implement daily computation under Rule 15c3-3. I am pleased the Commission agrees that additional time is necessary to allow broker-dealers to avoid operational challenges with meeting the initial compliance date.”
This extension will provide more time for broker-dealers to make any necessary systems or operational changes to implement a daily computation requirement and test their new daily processes for compliance.
Newsfile Corp. est une société de service sur les communiqués de presse destinée pour des entreprises de toutes tailles. Avec une distribution de plus de 6 000 bases de données médiatiques et financières, Newsfile livre des communiqués de presse à un public mondial.
- Climate Challenge (Hainan Baoting) Europe Outreach Event s'est déroulé avec succès à Paris
- Xlence, sponsor Diamond du Trading Show 2025 à Casablanca
- Altimetrik et SLK Software unissent leurs forces pour créer un géant des services d'ingénierie axés sur l'IA
- Zayo se classe 2e au 2025 Channel Futures MSP 501 et renforce sa position de chef de file mondial des services gérés
- Gurobi lance un nouvel assistant IA pour offrir aux utilisateurs de l’optimisation un support et des ressources de manière instantanée
- PRD Therapeutics annonce le lancement d'une première étude chez l'humain pour PRD001